176 related articles for article (PubMed ID: 22766604)
1. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
5. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
6. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang HR; Wang MH; Lian GY; Wu DG
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):99-102. PubMed ID: 25613619
[TBL] [Abstract][Full Text] [Related]
7. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang H; Wang M; Lian G; Wu D
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
[TBL] [Abstract][Full Text] [Related]
8. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
He LR; Liu MZ; Li BK; Jia WH; Zhang Y; Liao YJ; Chen YC; Zhang LJ; Guan XY; Zeng YX; Kung HF; Xie D
Int J Cancer; 2010 Jul; 127(1):138-47. PubMed ID: 19904743
[TBL] [Abstract][Full Text] [Related]
9. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
10. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
11. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
[TBL] [Abstract][Full Text] [Related]
12. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
13. Analyzing simultaneous positive expression of EZH2 and P53 protein to improve predictive value in cervical squamous cell carcinoma.
Chen SQ; Zhang HM; Li JB; Jiang HY; Fan L; Kong LZ; Yao SZ
Int J Gynecol Cancer; 2014 Nov; 24(9):1653-8. PubMed ID: 25275664
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
15. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
17. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
18. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
[TBL] [Abstract][Full Text] [Related]
19. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
J Virol; 2019 May; 93(9):. PubMed ID: 30814291
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of expression of enhancer of zeste homolog 2 and 53 in cervical squamous cell carcinoma and intraepithelial neoplasia].
Zhang H; Chen S; Niu G; Jiang H; Yao S
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):597-601. PubMed ID: 25430026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
